Garcia C, Abrahami D, Polli A, Chu H, et al. Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons. Clin Lung Cancer 2024;25:634-642.
PMID: 39232917